Precigen Inc. (PGEN)
PGEN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/0001356090-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001356090 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.7M |
| Net income | -$250.6M |
| Operating income | -$110.5M |
| Net margin | -2588.2% |
| Operating margin | -1141.1% |
| Revenue growth | +146.7% |
| Cash | $30.2M |
| Total assets | $155.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 159.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $15.0M cash; operating cash flow -$18.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 358,549,980 (2026-10-30); 353,824,499 a year earlier; 248,919,096 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Baltimore, Maryland, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25K, sold $44.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $74.1M | $35.8M | $11.9M | $15.0M | $94.3M | $156.9M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $55.0M | $20.1M | -$17.8M | $16.3M | $93.9M | $85.7M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $23.3M | -$7.9M | -$43.8M | $7.5M | $93.5M | $31.6M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $4.6M | -$23.5M | -$23.5M | $30.2M | $93.2M | $9.7M | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $2.9M | -$146.3M | -$29.1M | $14.3M | $92.9M | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $856K | -$26.6M | -$19.0M | $13.8M | No debt tags | Needs four quarters | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $1.3M | -$54.2M | -$16.3M | $6.1M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | Not filed | -$19.7M | -$8.2M | $29.5M | $0 | $3.9M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2025-08-19 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.6% |
| 1 month | -39.3% |
| 3 months | -30.0% |
| Year to date | +8.6% |
| 1 year | +17.6% |
| From 52-week high | -47.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| KRSA | Korsana Biosciences Inc. | $32.68 | +3.25% | $1.5B |
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier